



California State Board of Pharmacy
2720 Gateway Oaks Drive, Suite 100
Sacramento, CA 95833
Phone: (916) 518-3100 Fax: (916) 574-8618
www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency
Department of Consumer Affairs
Gavin Newsom, Governor



Notice of Meeting and Agenda Teleconference Legislation and Regulation Committee Meeting

DATES & TIMES: July 18, 2023, 2:00 p.m.

Place: Department of Consumer Affairs
1625 N. Market Blvd, First Floor Hearing Room
Sacramento, CA 95834

The Board is providing members of the public with different options to observe or participate in the meeting.

FOR OBSERVATION AND PUBLIC COMMENT IN PERSON:

Department of Consumer Affairs
1625 N. Market Blvd, First Floor Hearing Room
Sacramento, CA 95834

FOR PUBLIC PARTICIPATION AND COMMENT FROM A REMOTE LOCATION, PLEASE LOG ON TO WEBEX:

To access the WebEx event, attendees will need to click the following link and enter a first name, last name, email, and the event password listed below:

<https://dca-meetings.webex.com/dca-meetings/j.php?MTID=mb6da6d2ab31b9e5613fa88a065f58cbb>

If joining using the link above

Webinar number: 2494 908 8328

Webinar password: CSBP07182023

If joining by phone

+1-415-655-0001 US Toll

Access code: 249 490 88328

Passcode: 27270718

Members of the public participating via WebEx will be able to hear the meeting and provide public comment but may not be able to observe the meeting. The preferred audio connection is via phone bridge. The phone number and access code will be provided as part of your connection to the meeting. General instructions for using WebEx can be found at the end of the agenda.

Members of the public may but are not obligated to provide their names or personal information as a condition of observing or participating in the meeting. When signing into the WebEx platform, participants may be asked for their name and email address. Participants who choose not to provide their names will need to provide a unique identifier such as their initials or another alternative, so that the meeting moderator can identify individuals who wish to make public comment; participants who choose not to provide their email address may utilize a fictitious email address in the following sample format: XXXXX@mailinator.com.

FOR OBSERVATION ONLY:

Livestream: The Committee plans to webcast this meeting on the Department of Consumer Affairs' website at <https://thedcapage.blog/webcasts>. Livestream will be available at the earliest at 2:00 p.m. July 18, 2023. Using the Livestream link will allow only for observation with closed captioning. Livestream availability cannot, however, be guaranteed due to resource limitations or technical difficulties. The meeting will not be cancelled if Webcast is unavailable. If you wish to participate, please plan to participate via the WebEx option listed above.

Important Notices to the Public: The Legislation and Regulation Committee will hold a meeting in person that also includes participation by the public either in person at the public location identified on the first page of this agenda or via WebEx – access information is provided above. General instructions for using WebEx are attached to the agenda. The meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Debbie Damoth at (916) 518-3090, emailing Debbie.Damoth@dca.ca.gov, or sending a written request to the Board of Pharmacy, 2720 Gateway Oaks Drive, Suite 100, Sacramento CA 95833. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.

The time and order of agenda items are subject to change at the discretion of the Committee Chair. In the event a quorum of the Committee is unable to attend the meeting, or the Committee is unable to maintain a quorum once the meeting is called to order, the members present may, at the Chair's discretion, continue to discuss items from the agenda and make recommendations to the full board at a future meeting.

Government Code section 11125.7 provides the opportunity for the public to address each agenda item during discussion or consideration by the Committee or prior to the Committee taking any action on said item. Members of the public will be provided appropriate opportunities to comment on any issues before the Committee, but the Chair may, at his or her discretion, apportion available time among those who wish to speak. If public comment is not specifically requested, members of the public should feel free to request an opportunity to comment. Individuals may appear before the Committee to discuss items not on the agenda; however, the Committee can neither discuss nor take official action on these items at the time of the same meeting (Government Code sections 11125, 11125.7(a)).

Agenda

Discussion and action may be taken on any item on the agenda.

July 18, 2023

I. Call to Order, Establishment of Quorum, and General Announcements**II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings**

Note: The Committee may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. (Government Code sections 11125, 11125.7(a)).

III. Approval of the April 19, 2023 Legislation and Regulation Committee Meeting Minutes**IV. Discussion and Consideration of Pending Legislation Impacting the Practice of Pharmacy, the Board's Jurisdiction, or Board Operations**

- a. Assembly Bill 317 (Weber) Pharmacist Service Coverage
- b. Assembly Bill 663 (Haney) Pharmacy: Mobile Units
- c. Assembly Bill 782 (Lackey) Pharmacies: Compounding
- d. Assembly Bill 913 (Petrie-Norris) Pharmacy Benefit Managers
- e. Assembly Bill 1060 (Ortega) Health Care Coverage: Naloxone Hydrochloride
- f. Assembly Bill 1286 (Haney) Pharmacy
- g. Assembly Bill 1341 (Berman) Public Health: COVID-19 Testing and Dispensing Sites: Oral Therapeutics
- h. Assembly Bill 1557 (Flora) Pharmacy: Electronic Prescriptions
- i. Senate Bill 339 (Weiner) HIV Preexposure Prophylaxis and Postexposure Prophylaxis
- j. Senate Bill 345 (Skinner) Health Care Services: Legally Protected Health Care Services
- k. Senate Bill 427 (Portantino) Health Care Coverage: Antiretroviral Drugs, Devices, and Products
- l. Senate Bill 544 (Laird) Bagley-Keene Open Meetings Act: Teleconferencing
- m. Senate Bill 816 (Roth) Professions and Vocations
- n. Senate Bill 873 (Bradford) Prescription Drugs: Cost Sharing
- o. Senate Bill 887 (Senate Business, Professions, and Economic Development Committee) Consumer Affairs

V. Discussion and Consideration of Board Adopted Regulations – Board Staff Drafting Final Rulemaking Documents

- a. Proposed Regulation to Amend Title 16 CCR section 1707.6 Related to the Notice to Consumer
- b. Proposed Regulation to Add Title 16 CCR section 1715.1 Related to the ADDS Self-Assessment

VI. Discussion and Consideration of Board Approved Regulations Undergoing Pre-Notice

Review by the Department of Consumer Affairs, or Business, Consumer Services and Housing Agency

- a. Proposed Regulation to Amend Title 16 CCR section 1709.1 Related to the Designation of Pharmacist-in-Charge
- b. Proposed Regulation to Add Title 16 CCR section 1750 and 1750.1 Related to Outsourcing Facilities
- c. Proposed Regulation to Amend Title 16 CCR section 1746.3 Related to Opioid Antagonist
- d. Proposed Regulation to Add Title 16 CCR section 1746.6 Related to Medication Assisted Treatment Protocol
- e. Proposed Regulation to Amend Title 16 CCR section 1760 Related to Disciplinary Guidelines
- f. Proposed Regulation to Amend Title 16 CCR section 1732.5 and Add section 1732.8 Related to Continuing Education

VII. Discussion and Consideration of Board Approved Regulations – Board Staff Drafting Initial Rulemaking Documents

- a. Proposed Regulation to Amend Title 16 CCR section 1708.2 Related to Discontinuance of Business
- b. Proposed Regulation to Amend Title 16 CCR section 1711 Related to Quality Assurance
- c. Proposed Regulation to Amend Title 16 CCR sections 1735 and 1751 Related to Compounding

VIII. Discussion and Consideration of Board Authorized Section 100 – Board Staff Drafting Section 100 Documents

- a. Proposed Regulation to Amend Title 16 CCR sections 1715 and 1784 Related to the Community Pharmacy, Hospital Pharmacy, and Dangerous Drug Distributor Self-Assessment Forms

IX. Discussion and Consideration of Committee’s Strategic Goals

X. Future Committee Meeting Dates

XI. Adjournment

Upon conclusion of business